Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.
ImmunityBio, Inc. reports developments as a commercial-stage biotechnology company focused on immunotherapies designed to activate innate and adaptive immune responses for cancer and infectious disease. Its news centers on ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used with BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
Recurring updates cover ANKTIVA product revenue and unit demand, global regulatory authorizations and commercial availability, distribution partnerships, and scientific presentations involving bladder cancer, lung cancer, and broader IL-15 oncology programs. Company announcements also address BCG-naïve NMIBC clinical development, FDA promotional-compliance correspondence, and financing arrangements tied to revenue interests and convertible debt.
ImmunityBio, Inc. (NASDAQ: IBRX) announced the publication of preclinical data in the Journal for ImmunoTherapy of Cancer, showcasing their PD-L1 t-haNK therapy's effectiveness in combination with T cell-based immunotherapy for treating heterogeneous tumors. The study suggests a sequential treatment approach using T cell immunotherapy followed by PD-L1 t-haNKs to enhance tumor control in relapsed solid cancers. Currently, ImmunityBio is conducting Phase 1/2 QUILT trials and has over 40 clinical trials underway across multiple cancer types.
ImmunityBio, Inc. (NASDAQ: IBRX) has announced the safety review results for its Phase Ib trials of a COVID-19 vaccine utilizing hAd5 technology. The independent Safety Review Committee recommended continuing the trials, which include 80 participants across sublingual and oral formulations. No serious adverse events were reported. Preliminary data from a BARDA-funded non-human primate study showed complete protection against the virus challenge. The trials aim to optimize administration routes for the vaccine, with enrollment expected to complete in Q2.
ImmunityBio, Inc. (NASDAQ: IBRX) announced the development of a novel hAd5 ACE2 Decoy therapeutic vaccine targeting SARS-CoV-2, including key mutations E484K and N501Y. Presented at the 28th CROI, the findings highlight the vaccine’s high binding affinity to these variants. The ACE2 Decoy aims to compete with natural ACE2 receptors in the respiratory tract to trap the virus and prevent infection. Given the rapid emergence of COVID-19 variants, this advancement is crucial for treatment and prevention efforts, warranting further clinical development.
ImmunityBio (NASDAQ: IBRX) has commenced trading as a large-cap company with approximately 398 million fully diluted shares following its merger with NantKwest. The combined entity is now listed on the Global Select Market of Nasdaq. ImmunityBio specializes in late-stage immunotherapy, focusing on innovative therapies for cancer and infectious diseases, backed by a pipeline of over 40 clinical trials in development across 19 indications. Its lead product, Anktiva™, has received favorable FDA designations for certain bladder cancer treatments.